For teens who have struggled with obesity, it probably sounded too good to be true: a weekly injection that could help them control their eating and lead to weight loss. But the results of the clinical trial on the drug semaglutide, released earlier this month in the New England Journal of Medicine and presented at the discipline’s major conference, Obesity Week, turned out to be better than anything the participants — or even the researchers — expected.